Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I study of BVX-0918A in Stage III/Stage IV Ovarian Cancer

Trial Profile

A Phase I study of BVX-0918A in Stage III/Stage IV Ovarian Cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 13 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BVX-0918A (Primary)
  • Indications Ovarian cancer
  • Focus Adverse reactions
  • Sponsors BioVaxys
  • Most Recent Events

    • 08 Jun 2022 According to a BioVaxys media release, BioVaxys President and Chief Operating Officer Kenneth Kovan stated that completion of OVCAR-3 cell banks is another step towards our ability to produce GMP yields of BVX-0918, and brings the company closer to this Phase I study in the EU planned for later this year.
    • 01 Jun 2021 According to a BioVaxys media release, first phase of bioproduction has been begun,w construction of a new GMP clean room facility needed for producing clinical supply of BVX-0918.Bio Elpida will work with BioVaxys to prepare the manufacturing section of the CTA for the EU. Upon acceptance of the CTA, the second phase of the engagement would then commence, which is the manufacturing and testing of clinical samples for administration to patient for this trial.
    • 01 Jun 2021 According to a BioVaxys media release, this trial is planned for Q2 next year.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top